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ABSTRACT
Background: Human interferon-gamma (hIFN-γ) is produced by lymphocytes and has a variety of biological
properties. Measurement of hIFN-γ is widely used for various immunological responses for allergic or autoim-
mune diseases. Enzyme-linked immunosorbent assay (ELISA) is an established immunoassay used to quan-
tify cellular metabolites or cytokines. ELISA requires many incubation and wash steps and is not practically
suitable for screening large numbers of samples．
Methods: We have developed a fluorescence-linked immunosorbent assay (FLISA) method for the detection
of hIFN-γ. We measured the 50% inhibitory concentration (IC50) value of the hIFN-γ production by interleukin
(IL)-18 binding protein and anti-IL-18 monoclonal antibody. The IC50 described by FLISA was compared with
that by ELISA.
Results: We developed a new system for measuring hIFN-γ using Allophycocyanine (APC) fluorescent protein
and compared it with the previous method using Cy5.5. The proposed FLISA had a smaller coefficient of vari-
ation than ELISA, and the means of coefficient of variation using the same samples measured by ELISA and
FLISA were, respectively, 11.1% and 3.8%, suggesting that the edge effect often giving non-specific results
may be smaller in FLISA than in ELISA．
Conclusions: The improved FLISA system proposed is ideally suited for efficient measurements of hIFN-γ.
This homogeneous and multiplex method will be a powerful tool for high throughput screening for drug discov-
ery research．
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INTRODUCTION
Several studies have shown that cytokines participate
in the induction and effecter phases of inflammatory
responses in allergies . Studies of the cytokine net-
work are important for identifying candidates for
drugs or drug targets. In addition, measurement of
cytokines is required for screening of drugs. 1 The
regulation of human interferon-gamma (hIFN-γ ) is
particularly important for protective immunity in Th1
cells.2 hIFN-γ is implicated with interleukin (IL)-12 in
the adoption of a Th1 phenotype. On the other hand,
Th2 cytokines such as IL-4, IL-5, IL-10, and IL-13 af-
fect allergic responses.3,4 Many studies have shown
that hIFN-γ secretion associated with IL-12 or 18
plays an important role in the Th1 and Th2 balance.5,6
Hence, measurement of hIFN-γ has been widely used
for monitoring immune responses in allergic diseases
such as atopic dermatitis.7,8
Enzyme-linked immunosorbent assay (ELISA) is
an established immunoassay used to quantify various
cytokines. Conventional ELISA, which is not readily
amenable for screening large numbers of samples in
drug screenings, requires many processes and large
quantities of antibody. For drug discovery and devel-
opment , high throughput screening (HTS) would
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Fig. 1 Homogeneous assay is the main characteristic of 
FLISA. An FMAT○R  8100 HTS has a macro confocal imag-
ing system with a helium/neon laser, which automaticaly fo-
cuses on and scans fluorescent-bound beads resting on the 
botoms of multiwel trays. Because the depth of focus, 100 
μm, is smal in comparison with the remaining volume, back-
ground fluorescence is minimal in relation to bead-bound 
fluorescence; thus, there are no washing steps to remove 
unbound fluorophores. 
100 µm
633 nm He/Ne
laser
benefit from an immunoassay that requires minimal
manipulation and uses just a small amount of the
compounds required. Fluorescence-linked immuno-
sorbent assay (FLISA) is particularly well suited for
HTS.9
We have developed a FLISA method for the meas-
urement of hIFN-γ. We constructed the assembly of
capture antibody and fluorescent conjugated detec-
tion antibody for our FLISA system. This system en-
ables high throughput measurement of hIFN-γ and
could be applied to the assessment of other cytokines
or chemical mediators in allergic responses．
METHODS
INSTRUMENTATION
A fluorescent microvolume assay technology
(FMATⓇ) instrument consists of a detector (Applied
Biosystems, Tokyo, Japan) integrated with a bar code
reader and robotic plate handler (Zymark Corp, MA,
USA) that can accommodate 60 plates. An FMATⓇ
8100 HTS has a macro confocal imaging system with
a heliumneon (HeNe) laser (633 nm) which auto-
matically focuses on and scans fluorescent-bound
beads resting on the bottoms of multiwell trays. The
laser performs 256 scans across an area 1 mm × 1
mm×100 μm deep (Fig. 1). Because the depth of fo-
cus, 100 μm, is small in comparison with the remain-
ing volume, background fluorescence is minimal in
relation to bead-bound fluorescence;thus, there are
no washing steps to remove unbound fluorophores.
The emitted fluorescence passes through the same
optical path as the excitation beam and through a di-
chroic beam splitter for detection by photomultiplier
tubes through the filters (680―730 nm)．
PREPARATION OF ANTIBODY COATED BEADS
200 μl of streptavidin beads (0.5% wv;6 μm bead di-
ameter;SVP-60-55, Spherotech, were diluted in 800 μl
of phosphate-buffered saline (PBS) +0.01% sodium az-
ide (NaN3). After centrifugation at 10,000 g for 2min-
utes, the supernatant was discarded and resuspended
in 1 ml of PBS+0.01% NaN3. Next, a 4 μg portion of
biotinylated mouse anti-hIFN-γ monoclonal antibody
(mAb)(AHC4539, Biosource, California, USA) was
added to the streptavidin beads solution and incu-
bated with gentle mixing for 18 hours at room tem-
perature. Washing was repeated 2 times and the cap-
ture antibody coated beads were stocked in PBS +
0.01% NaN3 (8.4 × 106 beadsml ) at 4℃．
PREPARATION OF RECOMBINANT hIL-18 PRO-
TEIN
We used recombinant wild-type hIL-18 for the inhibi-
tion assay. Expression and purification were carried
out as described previously with minor modifica-
tions.10-12 The concentration of purified hIL-18 protein
was estimated using the absorbance constant (6160)
for hIL-18．
PREPARATION OF hIFN-γ BIOLOGICAL SAMPLE
hIL-18 inhibition assay based on hIFN-γ induction
was carried out as previously described.13,14 Briefly,
human myelomonocytic KG-1 cells (ATCC CCL246)
were grown in a culture medium consisting of RPMI
1640 supplemented with 10% heat-inactivated fetal calf
serum , L-glutamine ( 2 mmol L) , penicillin
(100 UmL) and streptomycin (100 μgmL). hIL-18
prepared at our laboratories (in a final concentration
of 2 ngml ) was preincubated with anti-hIL-18 mAb
(Medical & Biological Laboratories, Nagoya, Japan)
or hIL-18 binding protein Fc chimera (IL-18BP)(Re-
search and Development Systems Inc, Minneapolis,
USA)(in final concentrations between 0 and 500 ng
ml ) at 37℃ for 1 hour and then 100 μl of the mixture
added to 100 μl of KG-1 cells (3 × 106 cellsml ) per
well in a 96-well plate (Nunc, Roskilde, Denmark), fol-
lowed by incubation at 37℃ for 24 hours in 5% CO2.
The culture supernatants were collected , and the
hIFN-γ production in each of the samples was deter-
mined by ELISA (Japan Immunoresearch Laborato-
ries, Co. Ltd., Takasaki, Japan) and FLISA. Data are
presented as the percent inhibition of total hIFN-γ
production in the absence of hIL-18 antagonists. IC50,
the concentration of antagonists required to inhibit
50% of hIFN-γ production by KG-1 cells stimulated
with hIL-18, was then calculated．
FLUOROMETRIC MICROVOLUME IMMUNOAS-
SAY FOR hIFN-γ
A 50μl aliquot of sample or hIFN-γ standard (Re-
search and Development Systems Inc) was placed
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Fig. 2 Detection of fluorescence-linked beads in the wels with various concentrations of hIFN-γ. 
The intensity of the bead-bound fluorescence increased according to the hIFN-γ concentration.
0 pg/ml 500 pg/ml 1000 pg/ml
Fig. 3 The standard curve for hIFN-γ obtained with FLISA. 
The linear dynamic range for hIFN-γ was 3.9 ― 1,500 ng/ml. 
Each data point represents the average of triplicate assays.
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into a 96-well plate. 50 μl of beads mixture (antibody
beadss : allophycocyanin ( APC ) conjugated mouse
anti-hIFN-γ mAb (554702, Pharmingen , California ,
USA)s:FLISA buffer (PBS, 1% BSA, 0.35 M NaCl, 0.1%
Tween-20, 0.01% NaN3) =100 : 6.4 : 6500 ) was then
mixed with the sample or standard in each well and
incubated for 4 hours overnight at room temperature
in the dark. After incubation, the 96-well plate was
scanned using the FMATⓇ scanner . The average
fluorescence per bead was recorded.
RESULTS
FMATⓇ 8100 HTS includes a bead-based assay sys-
tem and is designed to negate the unbound fluores-
cent dye-labeled antibody. At measurement, FMATⓇ
scans for fluorescent-bound beads resting on the bot-
tom of multiwell trays (Fig. 1). No beads are found in
the upper portions of the wells and non-specific fluo-
rescence is not involved in background fluorescence
intensity. In the lower 100 μm of the wells, the signals
of unbound fluorescent dye-labeled antibody are de-
leted due to the limited size and form of the beads.
Actually, the fluorescence intensity of negative con-
trol wells is 31.6＋－2.1 and that of the wells, which
have 3.9 pgml of the minimum IFN-γ is 77.2＋－
4.9. This is an obvious difference between negative
control wells and minimum IFN-γ wells．
A standard solution of hIFN-γ was two-fold serially
diluted in RPMI-1640 + 10% FCS. The intensity of the
bead-bound fluorescence increased according to
hIFN-γ concentration (Fig. 2). A standard curve for
hIFN-γ was generated using the FMATⓇ scanner
(Fig. 3). The linear dynamic range of hIFN-γ by
FLISA was 3.9―1500 pgml. These results indicate
that our system can recognize minute changes of
hIFN-γ values. With previously established methods
for IL-6 and IL-8, the linear dynamic ranges were
15.6―1000 pgml and 15.6―2000 pgml, respectively.
Our FLISA system has an equivalent dynamic range
comparable to these results, 9 a range that is suffi-
cient to be applied in clinical use.
To test whether FLISA could accurately quantify
hIFN-γ in a biological sample , inhibition assays of
hIL-18 were performed.15,16 We measured about 150
samples using FLISA and about 90 samples using
ELISA. Sample preparation time of FLISA was equal
to that of ELISA. hIFN-γ produced by KG-1 cells was
measured using ELISA and FLISA (Figs . 4A, 4B).
hIL-18 was neutralized by anti-hIL-18mAb or IL-18BP
before stimulation. The IC50s for anti-hIL-18mAb and
hIL-18BP using FLISA were 19.7 ngml and 5.2 ng
ml, respectively (Fig . 4B). Similarly , those using
ELISA were estimated as 27 ngml and 5.4 ngml,
respectively (Fig . 4A). However , as shown in Fig-
ure 4, the results of ELISA did not show a regression
curve suitable for estimating precise IC50 values. The
means of the coefficient of variation using the same
samples measured by ELISA and FLISA were respec-
tively 11.1% and 3.8%, suggesting that the edge effect
often giving non-specific results may be smaller in
FLISA than in ELISA．
Our proposed FLISA method was modified to use a
combination of capture antibody and fluorescent dye-
labeled detection antibody . As shown in Figure 5,
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Fig. 4 Inhibition assay of hIL-18 by hIL-18BP or anti-hIL-
18 mAb. hIL-18 (final concentration 2 ng/ml) was incubated 
with two-fold dilutions of anti-hIL-18 mAb or hIL-18BP for 1 
hour at 37°C. After this incubation, the mixtures were added 
to KG-1 cels, and after 24 hours hIFN-γ was measured. The 
stimulation control of hIL-18 (2 ng/ml) was set at 100%, and 
the percent change was calculated for each concentration 
of anti-hIL-18mAb or hIL-18BP. Each data point represents 
an average of triplicate assays. (A) The inhibition curve 
measured by ELISA. (B) The inhibition curve measured by 
FLISA. The solid circle shows the inhibition of hIL-18 by hIL-
18BP. The solid square shows the inhibition of hIL-18 by 
anti-hIL-18 mAb. 
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Fig. 5 Schematic diagram of our FLISA method (A) and a 
previous method (B). (A): (a) streptavidin beads. (b) biotiny-
lated mouse monoclonal anti-hIFN-γ  mAb.  (c) hIFN-γ sam-
ple. (d) APC conjugated mouse monoclonal anti-hIFN-γ 
mAb beads.  (B): (a) goat anti-mouse IgG(Fc) beads. (b) 
mouse anti-hIFN-γ  mAb. (c) hIFN-γ sample. (d) Cy5.5 con-
jugated mouse anti-hIFN-γ mAb.
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Fig. 6 The standard curve for hIFN-γ obtained with our 
newly proposed FLISA method (solid circles) and the previ-
ously reported FLISA method (open circles). The sensitivity 
of our method was about four-fold higher than that of the 
previously reported method.
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streptavidin beads and a biotinylated mouse anti-
hIFN-γmAb were used as IFN-γ capture particles and
APC conjugated mouse anti-hIFN-γ mAb was used as
the IFN-γ detection reagent . Previously , goat anti-
mouse IgG (Fc) beads and mouse anti-hIFN-γ mAb
have been used as the IFN-γ capture particles and Cy
5.5 conjugated mouse anti-hIFN-γ mAb as the IFN-γ
detection reagent. Figure 6 shows our standard curve
for IFN-γ estimated IFN-γ values in detail compared
with that from the previously proposed FLISA
method．
DISCUSSION
When measuring various cytokines, the effect of the
environmental temperature is one of the factors influ-
encing inter-experimental accuracy. ELISA requires
washing and application of a detection antibody fol-
lowing the first incubation, and washing and applica-
tion of a detecting reagent following the second incu-
bation . On the other hand , with FLISA, measure-
ments can be performed following the first incuba-
tion. In all ELISA steps it is therefore very easy to ex-
pose the samples to environmental temperatures .
The edge effect, which is the difference in tempera-
ture between the outer and inner wells, is therefore
one of the factors resulting in inter-experimental er-
rors . 17,18 Accurate screenings are very much re-
quired in working toward drug discoveries.19,20
We used two kinds of mouse hIFN-γ mAb in our
FLISA method;one a capture antibody, the other an
APC conjugated antibody as a detection antibody .
Measurements of hIFN-γ in a previous report used a
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goat anti-mouse IgG antibody as the bead-coating an-
tibody and two kinds of mouse anti-hIFN-γ mAb, a
capture antibody and a Cy5.5 conjugated antibody
(Fig. 5). 21 The sensitivity of our proposed FLISA
method was about four-fold higher than that of previ-
ous methods (Fig. 6). That is, the minimum unit for
measurement in our method is four times smaller;0.5
pgmlfluorescence (FL) in the previous method by
Komatsu et al. , 0.125 pgmlFL in our method .
Therefore, we were able to obtain detailed IFN-γ val-
ues. The sensitivity of the FLISA method proposed in
this paper allowed the discrimination between differ-
ences．
The sensitivity of each method may depend on the
structural difference between APC and Cy5.5. One
APC molecule bounds to one antibody. The APC is a
trimer that consists of α and β subunits (αβ)3. Each
subunit has one fluorophore;so as a result an APC
conjugated antibody contains six fluorophores
(Fig. 5A).22 However, one Cy5.5 binds to one anti-
body, and the Cy5.5 is a single fluorophore itself .
Thus an antibody conjugated Cy5.5 has one fluoro-
phore (Fig. 5B). Although the fluorescent dyeanti-
body ratio of APC is equal to that of Cy5.5, an APC
conjugated antibody has six times as many fluoro-
phores as a Cy5.5 conjugated antibody. The differ-
ence in fluorescence intensity may also be a factor in-
creasing sensitivity．
To quantify hIFN-γ in large amounts of sample, we
developed a more efficient assay method than con-
ventional ELISA, which can involve many incubation
and washing steps, and requires large amounts of an-
tibodies.9 In contrast, our FLISA method is a homo-
geneous bead-based immunoassay that requires no
wash steps. Over 100-fold less capture antibody is
needed in FLISA than in conventional ELISA.7 How-
ever, the most striking difference is the time required
for the assay. In our study, the occupation time of the
FLISA method was about 1 hour, demonstrating that
FLISA can be performed in a much shorter time than
conventional ELISA, which requires about 5 hours.23
A minimal time requirement is a crucial factor for ap-
plications such as HTS in drug discovery research.
FLISA is thus an attractive method as it involves less
hands-on time and lower running costs.21
In immunological studies using FLISA, measure-
ments of IL-6 and IL-8 and CD3+CD4+ lymphocyte
counts in whole blood have been reported.9,24 The
bead-based system of the FLISA is readily applicable
to any other plate-based assay , such as non-
radioactive kinase, phosphatase, and protease assays.
A multiplexed bead-based receptor-ligand binding as-
say has already been demonstrated using FLISA.25,26
In addition, FLISA is capable of detecting and quanti-
fying fluorescence on live cells, allowing for such di-
verse assays as apoptosis and cytotoxicity, and cellu-
lar immunoassays, and receptor ligand binding as-
says.25-28 The FLISA system can be adapted for HTS
of large libraries of chemical and natural products ,
thus having a place in any laboratory that routinely
performs multiple, repetitive assays．
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